Chongqing Taiji Industry(Group) Co.,Ltd (SHSE: 600129)
Health Care · Pharmaceuticals · CN
CN¥15.07
-11.46% today · -36.4% 1Y
Chongqing Taiji Industry(Group) Co.,Ltd (SHSE: 600129) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.24B and employs 10,864 people.
Over the last twelve months the share price has lost 36.4%, trading between 11.56 and 23.98.
Tweenvest scores Chongqing Taiji Industry(Group) Co.,Ltd across four factors: quality 57/100, value 38/100, growth 11/100. Its strongest factor is quality.
600129 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.24B
- Revenue (TTM)
- $1.48B
- P/E
- 73.08
- EPS
- 0.21
- Dividend yield
- —
- Beta (5Y)
- 0.20
- 52-week high
- CN¥23.98
- 52-week low
- CN¥11.56
- Avg volume (3M)
- —
- Shares outstanding
- 551.42M
- Employees
- 10,864
- Next earnings
- —
About Chongqing Taiji Industry(Group) Co.,Ltd
Chongqing Taiji Industry (Group) Co.,Ltd operates as a pharmaceutical enterprise, conducting business both within China and across international markets. The company focuses on the research, development, manufacturing, and distribution of traditional Chinese medicines and various health products. Its offerings are available in a wide array of formats, including tablets, oral liquids, syrups, dripping pills, granules, capsules, tinctures, and powders. The product line addresses a comprehensive range of health conditions and therapeutic areas. These include disorders of the digestive and respiratory systems, cardiovascular and cerebrovascular ailments, pediatric and gynecological health, systemic anti-infective agents and antibiotics, pain relief medications, orthopedic treatments, remedies for colds and coughs, and drugs for the endocrine and nervous systems. The firm's headquarters are situated in Chongqing, China.
- ISIN
- CNE000000TQ2
- Founded
- 1979
- Listed since
- Nov 18, 1997
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.